Literature DB >> 28940014

Clinicopathological analysis in PTCL-NOS with CADM1 expression.

Takeharu Kato1,2, Hiroaki Miyoshi3, Seiichiro Kobayashi4, Noriaki Yoshida1, Yoshitaka Imaizumi5, Masao Seto1, Kaoru Uchimaru6, Yasushi Miyazaki2,5, Koichi Ohshima1.   

Abstract

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), is a heterogeneous disease with respect to clinicopathological features. Cell adhesion molecule 1 (CADM1) has been reported to be ectopically expressed in adult T cell leukaemia/lymphoma (ATLL). However, the frequency of CADM1 expression remains unknown in peripheral T cell lymphomas. In the current study, CADM1 expression was analysed in 88 PTCL-NOS patients. CADM1 was expressed in 14 of 88 (15.9%) PTCL-NOS cases, and its expression was associated with C-C chemokine receptor type 4 (CCR4) expression and nuclear atypia. CADM1-positive PTCL-NOS cases (10/74) had a significantly poorer prognosis than CADM1-negative cases (64/74) (P = 0.001). Multivariate analysis confirmed that CADM1 expression was an independent prognostic factor in PTCL-NOS. These findings suggest that CADM1 expression is a novel prognostic factor for PTCL-NOS.

Entities:  

Keywords:  CADM1; Clinicopathological analysis; Peripheral T cell lymphoma, not otherwise specified; Prognosis

Mesh：

Substances：

Year:  2017        PMID： 28940014     DOI： 10.1007/s00428-017-2233-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


  30 in total

1.  Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia.

Authors:  Y Yamada; K Murata; S Kamihira; S Atogami; K Tsukasaki; H Sohda; T Yanagisako; S Momita; T Jubashi; T Amagasaki
Journal:  Cancer       Date:  1991-05-15       Impact factor: 6.860

2.  Clinical significance of CADM1/TSLC1/IgSF4 expression in adult T-cell leukemia/lymphoma.

Authors:  S Nakahata; Y Saito; K Marutsuka; T Hidaka; K Maeda; K Hatakeyama; T Shiraga; A Goto; N Takamatsu; Y Asada; A Utsunomiya; A Okayama; Y Kubuki; K Shimoda; Y Ukai; G Kurosawa; K Morishita
Journal:  Leukemia       Date:  2012-01-06       Impact factor: 11.528

3.  Expression of a splicing variant of the CADM1 specific to small cell lung cancer.

Authors:  Shinji Kikuchi; Miwako Iwai; Mika Sakurai-Yageta; Yumi Tsuboi; Takeshi Ito; Tomoko Maruyama; Hitoshi Tsuda; Yae Kanai; Masataka Onizuka; Yukio Sato; Yoshinori Murakami
Journal:  Cancer Sci       Date:  2012-05-15       Impact factor: 6.716

4.  Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphoma.

Authors:  S M Ansell; T M Habermann; P J Kurtin; T E Witzig; M G Chen; C Y Li; D J Inwards; J P Colgan
Journal:  J Clin Oncol       Date:  1997-06       Impact factor: 44.544

5.  Monitoring of interobserver agreement in nuclear atypia scoring of node-negative breast carcinomas judged at individual collaborating hospitals in the National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol.

Authors:  H Tsuda; F Akiyama; M Kurosumi; G Sakamoto; T Watanabe
Journal:  Jpn J Clin Oncol       Date:  1999-09       Impact factor: 3.019

Review 6.  Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis.

Authors:  Yoshinori Murakami
Journal:  Cancer Sci       Date:  2005-09       Impact factor: 6.716

7.  Aberrant expression of tumor suppressors CADM1 and 4.1B in invasive lesions of primary breast cancer.

Authors:  Yuka Takahashi; Miwako Iwai; Taketo Kawai; Atsushi Arakawa; Takeshi Ito; Mika Sakurai-Yageta; Akihiko Ito; Akiteru Goto; Mitsue Saito; Fujio Kasumi; Yoshinori Murakami
Journal:  Breast Cancer       Date:  2011-04-28       Impact factor: 4.239

8.  GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features.

Authors:  Tianjiao Wang; Andrew L Feldman; David A Wada; Ye Lu; Avery Polk; Robert Briski; Kay Ristow; Thomas M Habermann; Dafydd Thomas; Steven C Ziesmer; Linda E Wellik; Thomas M Lanigan; Thomas E Witzig; Mark R Pittelkow; Nathanael G Bailey; Alexandra C Hristov; Megan S Lim; Stephen M Ansell; Ryan A Wilcox
Journal:  Blood       Date:  2014-02-04       Impact factor: 22.113

9.  IGSF4 is a novel TCR ζ-chain-interacting protein that enhances TCR-mediated signaling.

Authors:  Hye-Ran Kim; Byeong-Hun Jeon; Hyun-Su Lee; Sin-Hyeog Im; Masatake Araki; Kimi Araki; Ken-ichi Yamamura; Suck-Chei Choi; Do-Sim Park; Chang-Duk Jun
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

10.  Identification of multiple subclones in peripheral T-cell lymphoma, not otherwise specified with genomic aberrations.

Authors:  Noriaki Yoshida; Akira Umino; Fang Liu; Kotaro Arita; Kennosuke Karube; Shinobu Tsuzuki; Koichi Ohshima; Masao Seto
Journal:  Cancer Med       Date:  2012-09-26       Impact factor: 4.452
View more
  2 in total

Review 1.  New developments in the pathology of malignant lymphoma. A review of the literature published from September-August 2017.

Authors:  J H van Krieken
Journal:  J Hematop       Date:  2017-11-29       Impact factor: 0.196

2.  Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.

Authors:  Fumiko Arakawa; Hiroaki Miyoshi; Noriaki Yoshida; Kazutaka Nakashima; Yosaku Watatani; Takuya Furuta; Kyohei Yamada; Mayuko Moritsubo; Mai Takeuchi; Eriko Yanagida; Yasumasa Shimasaki; Kei Kohno; Keisuke Kataoka; Koichi Ohshima
Journal:  Cancer Med       Date:  2021-09-03       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.